ITG(600755) 中银国际·2025-05-14 01:48Investment Rating - The report maintains an "Accumulate" rating for the company [2][4][6] Core Views - The company experienced a significant decline in revenue and net profit in 2024 due to a reduction in supply chain business scale and asset impairment losses. However, the first quarter of 2025 shows signs of recovery in operating quality and profitability [4][9] - Future profitability is expected to rebound as non-recurring impairment losses decrease and core business profitability stabilizes [4][6] Financial Summary - In 2024, the company reported operating revenue of RMB 354.44 billion, a decrease of 24.30% year-on-year, and a net profit attributable to shareholders of RMB 626 million, down 67.33% [4][9] - For Q1 2025, the company achieved operating revenue of RMB 70.53 billion, a decline of 27.19% year-on-year, but a net profit of RMB 422 million, an increase of 2.76% [4][9] - The projected net profits for 2025-2027 are RMB 1.27 billion, RMB 1.55 billion, and RMB 1.97 billion, representing growth rates of 103.6%, 21.8%, and 27.2% respectively [6][8] Valuation Metrics - The report adjusts the earnings per share (EPS) forecast for 2025-2027 to RMB 0.59, RMB 0.72, and RMB 0.91, with corresponding price-to-earnings (PE) ratios of 10.9, 8.9, and 7.0 [6][8] - The company’s EBITDA for 2025 is projected at RMB 3.07 billion, with a significant recovery expected in subsequent years [8][9] Strategic Outlook - The company is focusing on enhancing its supply chain management and international expansion, with plans to establish branches in countries like Vietnam and Germany [9] - The health technology segment is expected to grow, with a 49.61% increase in revenue to RMB 1.10 billion in 2024 [9]